Literature DB >> 7527295

Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors.

M Monne1, C M Croce, H Yu, E P Diamandis.   

Abstract

Prostate-specific antigen (PSA) is considered a highly specific biochemical marker of the prostate gland and is currently used for prostate cancer diagnosis and monitoring of patients with prostate adenocarcinoma. We recently demonstrated, however, that about 30% of female breast tumors produce a M(r) 33,000 protein that has striking similarities to seminal PSA. In this study we characterized the presence of PSA in 6 breast tumors and in the testosterone-stimulated T47D breast cancer cell line at the mRNA level. Using reverse transcriptase-polymerase chain reaction and DNA sequencing techniques we identified PSA mRNA in immunoreactive PSA-positive breast tumors but not in immunoreactive PSA-negative breast tumors. The sequence of the generated polymerase chain reaction products was identical to the sequence of the PSA complementary DNA derived from prostate tissue. The data presented here support the notion that breast tumors produce a M(r) 33,000 protein which is identical to PSA produced by the prostate gland. Our study suggests that the presence of PSA in breast tumors may be used as a new additional biochemical marker for breast cancer prognosis, for the spreading of hematogenous micrometastases, and/or for response to adjuvant treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527295

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Equivalent recognition of free and ACT-complexed PSA in a monoclonal-polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody.

Authors:  Z Zhou; E G Armstrong; A Belenky; J V Freeman; K K Yeung
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

2.  Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.

Authors:  H Yu; E P Diamandis; M Levesque; M Giai; R Roagna; R Ponzone; P Sismondi; M Monne; C M Croce
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 3.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

4.  Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.

Authors:  A Ylikoski; M Karp; K Pettersson; H Lilja; T Lövgren
Journal:  J Mol Diagn       Date:  2001-08       Impact factor: 5.568

Review 5.  Reconnoitring the status of prostate specific antigen and its role in women.

Authors:  Prakruti Dash
Journal:  Indian J Clin Biochem       Date:  2014-06-22

6.  Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; Edson J Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

7.  Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour.

Authors:  Elteza Tahjiba Jahir; Runi Devi; Bibhuti Bhushan Borthakur
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Does Rigid Cystoscopy Affect the Total Serum Prostate-Specific Antigen Levels?

Authors:  Iqbal Singh; Ravi Prasad; Vivek Agarwal; R L Tripathi
Journal:  Indian J Surg       Date:  2013-02-15       Impact factor: 0.656

9.  Quantification of prostate-specific antigen immunoreactivity in human breast cyst fluids.

Authors:  F Mannello; G Bocchiotti; G Bianchi; F Marcheggiani; G Gazzanelli
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

10.  Prostate specific antigen--a new constituent of breast cyst fluid.

Authors:  E P Diamandis; H Yu; C López-Otín
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.